Literature DB >> 8276723

Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate.

T Yamaguchi1, H Tsurumi, K Kitamura, E Otsuji, T Miyagaki, T Kotani, T Takahashi.   

Abstract

A human/mouse chimeric Fab monoclonal antibody A7 (chFabA7) was covalently coupled to neocarzinostatin (NCS) by the SPDP method at various chFabA7:NCS substitution ratios. The antigen-binding activity of the conjugate, examined by ELISA using fixed antigen-positive colon cancer cells, was identical to that of the parent chFabA7 when one mole of NCS was conjugated, but was reduced with 2 or 3 moles of conjugated NCS. By means of a colony-forming assay, the cytocidal effect of the conjugate on antigen-positive cancer cells was found to be stronger than that of free NCS, whereas in antigen-negative cancer cells it was similar to that of free NCS. This effect was attenuated by adding an excess amount of monoclonal antibody A7. These findings indicate that the conjugate has an antigen-specific cytocidal action, and thus chFabA7-NCS is a promising tool for targeting cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8276723      PMCID: PMC5919093          DOI: 10.1111/j.1349-7006.1993.tb02820.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  13 in total

1.  Binding, internalization and the cytotoxicity of monoclonal antibody A7-neocarzinostatin conjugates (A7-NCS) in target cells.

Authors:  K Kitamura; T Takahashi; A Noguchi; K Takashina; H Tsurumi; T Yamaguchi
Journal:  Tohoku J Exp Med       Date:  1990-07       Impact factor: 1.848

2.  Neocarzinostatin: spectral characterization and separation of a non-protein chromophore.

Authors:  M A Napier; B Holmquist; D J Strydom; I H Goldberg
Journal:  Biochem Biophys Res Commun       Date:  1979-07-27       Impact factor: 3.575

3.  Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer.

Authors:  K Kitamura; T Takahashi; T Yamaguchi; T Yokota; A Noguchi; T Amagai; J Imanishi
Journal:  Tohoku J Exp Med       Date:  1989-02       Impact factor: 1.848

4.  Specific and nonspecific macromolecule-drug conjugates for the improvement of cancer chemotherapy.

Authors:  E Hurwitz
Journal:  Biopolymers       Date:  1983-01       Impact factor: 2.505

5.  Biological activity of the antitumor protein neocarzinostatin coupled to a monoclonal antibody by N-succinimidyl 3-(2-pyridyldithio)-propionate.

Authors:  G Jung; W Köhnlein; G Lüders
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

6.  A monoclonal antibody against human colon cancers.

Authors:  H Kotanagi; T Takahashi; T Masuko; Y Hashimoto; K Koyama
Journal:  Tohoku J Exp Med       Date:  1986-04       Impact factor: 1.848

7.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Isolation of a non-protein component and a protein component from neocarzinostatin (NCS) and their biological activities.

Authors:  Y Koide; F Ishii; K Hasuda; Y Koyama; K Edo; S Kitamine; F Kitame; N Ishida
Journal:  J Antibiot (Tokyo)       Date:  1980-03       Impact factor: 2.649

9.  Human immune response to multiple injections of murine monoclonal IgG.

Authors:  D L Shawler; R M Bartholomew; L M Smith; R O Dillman
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

10.  Monoclonal antibody A7 tumor localization enhancement by its F(ab')2 fragments to colon carcinoma xenografts in nude mice.

Authors:  K Kitamura; T Takahashi; T Yamaguchi; S Kitai; T Amagai; J Imanishi
Journal:  Jpn J Clin Oncol       Date:  1990-06       Impact factor: 3.019

View more
  5 in total

1.  Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study.

Authors:  K Yamamoto; K Kitamura; S Nishida; D Ichikawa; K Okamoto; T Yamaguchi; T Takahashi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; H Matsumura; K Yamamoto; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

3.  Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; K Yamamoto; H Matsumura; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1997-02

4.  Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts.

Authors:  E Otsuji; T Yamaguchi; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Taniguchi; M Kato; T Kotani; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

5.  In vivo efficacy of neocarzinostatin coupled with Fab human/mouse chimeric monoclonal antibody A7 against human colorectal cancer.

Authors:  T Yamaguchi; H Tsurumi; T Kotani; N Yamaoka; E Otsuji; K Kitamura; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1994-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.